Madrigal Pharmaceuticals, Inc.2024财年第三财季实现净利润-1.07亿美元，同比减少8.37%

市场透视11-10

11月10日，Madrigal Pharmaceuticals, Inc.（MDGL.US）公布财报，公告显示公司2024财年第三财季净利润为-1.07亿美元，同比减少8.37%；其中营业收入为62.18百万美元，每股基本收益为-4.92美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.（MDGL.US）总负债2.96亿美元，其中短期债务878000.00美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482422487?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-10 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482422487","market":"us","top_or_hot":-1,"title":"Madrigal Pharmaceuticals, Inc.2024财年第三财季实现净利润-1.07亿美元，同比减少8.37%","media":"市场透视","content":"<div>\n<p>11月10日，Madrigal Pharmaceuticals, Inc.（MDGL.US）公布财报，公告显示公司2024财年第三财季净利润为-1.07亿美元，同比减少8.37%；其中营业收入为62.18百万美元，每股基本收益为-4.92美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.（MDGL.US）总负债2.96亿美元，其中短期债务878000.00美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000138abb0ffcf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Madrigal Pharmaceuticals, Inc.2024财年第三财季实现净利润-1.07亿美元，同比减少8.37%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMadrigal Pharmaceuticals, Inc.2024财年第三财季实现净利润-1.07亿美元，同比减少8.37%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-10 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000138abb0ffcf&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月10日，Madrigal Pharmaceuticals, Inc.（MDGL.US）公布财报，公告显示公司2024财年第三财季净利润为-1.07亿美元，同比减少8.37%；其中营业收入为62.18百万美元，每股基本收益为-4.92美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.（MDGL.US）总负债2.96亿美元，其中短期债务878000.00美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000138abb0ffcf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000138abb0ffcf&s=b","article_id":"2482422487","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241110000138abb0ffcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482422487","pubTimestamp":1731168072,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月10日，Madrigal Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第三财季净利润为-1.07亿美元，同比减少8.37%；其中营业收入为62.18百万美元，每股基本收益为-4.92美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.总负债2.96亿美元，其中短期债务878000.00美元，资产负债比为3.63，流动比率为5.98。机构评级：截至2024年11月10日，当前有15家机构对Madrigal Pharmaceuticals, Inc.目标价做出预测，其中目标均价为368.87美元，其中最低目标价为155.00美元，最高目标价为530.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"Madrigal Pharmaceuticals, Inc. achieved net profit of-$107 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 8.37%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"11月10日，Madrigal Pharmaceuticals, Inc.（MDGL.US）公布财报，公告显示公司2024财年第三财季净利润为-1.07亿美元，同比减少8.37%；其中营业收入为62.18百万美元，每股基本收益为-4.92美元。从资产负债表来看，Madrigal Pharmaceuticals, Inc.（MDGL.US）总负债2.96亿美元，其中短期债务878000.00美元，资产负债比为3.63，流动比率为5.98。机构评级：截至2024年11月10日，当前有15家机构对Madrigal Pharmaceuticals, Inc.目标价做出预测，其中目标均价为368.87美元，其中最低目标价为155.00美元，最高目标价为530.00美元。公司简介：Madrigal Pharmaceuticals Inc是一家临床阶段生物制药公司。它着重于心血管疾病和非酒精性脂肪性肝炎（NASH）的治疗剂开发及其商业化。该公司的产品MGL-3196，是一种口服小分子针对肝脏的β选择性THR激动剂，用于治疗非酒精性脂肪性肝炎和家族性高胆固醇血症。此外，MGL-3196还通过增加脂肪代谢来降低血浆和肝脏中的甘油三酯并展现出抗糖尿病作用。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482422487"}